Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-121 and Erlotinib in NSCLC
NCT00994123Phase 2Completed
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Feb 2010
- Primary completion
- Nov 2014
- Countries
- 6
01
Overview
A Phase 2 trial of seribantumab in non-small cell lung cancer (NSCLC), sponsored by Merrimack Pharmaceuticals. Started Feb 2010; status: completed.
02
Drugs
seribantumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00994123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00994123.